BIO Double Helix Sponsor
Sponsors

Company Profile

Deltanoid Pharmaceuticals

Biopharmaceuticals
Musculoskeletal
Metabolic

510 Charmany Drive
Madison, WI 53719
USA
www.deltanoid.com 		Incorporated in 1999
18 Employees 		Privately Held

This Year's Highlights

  • Deltanoid has a vitamin D analog in phase 2 clinical trials for treatment of osteoporosis. Deltanoid has full rights to this compound and is seeking potential partners for commercialization.
  • Deltanoid has compounds under preclinical development for renal disease, including a next generation vitamin D analog for the treatment of secondary hyperparathyroidism in kidney dialysis patients and a compound to control blood phosphorus.
  • Deltanoid has sublicensed a vitamin D analog which is in phase 2 trials by CollaGenex for the topical treatment of psoriasis.

Anticipated Highlights

  • Deltanoid also has compounds under development in the areas of autoimmune and skin diseases.

Corporate Mission

Deltanoid Pharmaceuticals Inc. provides a unique conduit through which university biopharmaceutical inventions can be moved rapidly from the lab to the clinic and eventually to the market